Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SVB Leerink

Why Are Accolade Shares Down Over 40% Today

Accolade Inc (NASDAQ:ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. The company reported a wider net loss of $(34.56) million compared to $(4.73) million a year ago. EPS loss came at $(0.51)…

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.

SVB Leerink Maintains Market Perform Rating for Rubius Therapeutics, Lowers Price Target To $3

SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount

Calithera Biosciences Inc (NASDAQ:CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of common stock is accompanied by a warrant to purchase one common share at an exercise price of $0.54 per share, which is immediately exercisable and will…

10 Biggest Price Target Changes For Wednesday

SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday.

inkl

Read news from The Economist, FT, and more,
with one subscription

10 Biggest Price Target Changes For Thursday

10 Biggest Price Target Changes For Thursday

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.

10 Biggest Price Target Changes For Friday

10 Biggest Price Target Changes For Friday

SVB Leerink cut Illumina, Inc. (NASDAQ: ILMN) price target from $430 to $400. Illumina shares fell 0.7% to $355.70 in pre-market trading.

Organisations

B of A Securities

Edwards Lifesciences

Guardant Health

Myovant Sciences

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

249,129 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play